Bladder Cancer - Results from #60

PD-L1 expression in muscle invasive urothelial carcinoma: Comparison of SP142 and SP263 assay. November 2, 2022

Whole-exome sequencing identified mutational profiles of urothelial carcinoma post kidney transplantation. November 2, 2022

Immune activation is essential for the antitumor activity of EZH2 inhibition in urothelial carcinoma. November 2, 2022

Linear Versus Parallel Metastatic Progression of Urological Cancers - Expert Commentary November 1, 2022

Quality improvement in managing patients with non-muscle-invasive bladder cancer by introducing a surgical checklist for transurethral resection of bladder tumor. November 1, 2022

m6A-immune-related lncRNA prognostic signature for predicting immune landscape and prognosis of bladder cancer. November 1, 2022

Photodynamic versus white-light-guided resection of first-diagnosis non-muscle-invasive bladder cancer: PHOTO RCT. October 31, 2022

Adjuvant nivolumab versus placebo following radical surgery for high-risk muscle-invasive urothelial carcinoma: a subgroup analysis of Japanese patients enrolled in the phase 3 CheckMate 274 trial. October 31, 2022

A systematic review and meta-analysis on delaying surgery for urothelial carcinoma of bladder and upper tract urothelial carcinoma: Implications for the COVID19 pandemic and beyond. October 28, 2022

Impact of the controlling nutritional status (CONUT) score on perioperative morbidity and oncological outcomes in patients with bladder cancer treated with radical cystectomy. October 28, 2022

Safety, Tolerability, and Long-Term Clinical Outcomes of an IL-15 analogue (N-803) Admixed with Bacillus Calmette-Guérin (BCG) for the Treatment of Bladder Cancer. October 28, 2022

APOBEC3B and CD274 as Combined Biomarkers for Predicting Response to Immunotherapy in Urothelial Carcinoma of the Bladder. October 27, 2022

Analysis and identification of the necroptosis landscape on therapy and prognosis in bladder cancer. October 27, 2022

Development of a Clinically Applicable NanoString-Based Gene Expression Classifier for Muscle-Invasive Bladder Cancer Molecular Stratification. October 26, 2022

Allyl-, Butyl- and Phenylethyl-Isothiocyanate Modulate Akt-mTOR and Cyclin-CDK Signaling in Gemcitabine- and Cisplatin-Resistant Bladder Cancer Cell Lines. October 26, 2022

Clinical Efficacy of Neoadjuvant Intravesical Mitomycin-C Therapy Immediately before Transurethral Resection of Bladder Tumor in Patients with Non-muscle-invasive Bladder Cancer: Preliminary Results of a Prospective, Randomized Phase II Study. October 26, 2022

Combining Antiandrogens with Immunotherapy for Bladder Cancer Treatment. October 26, 2022

Obesity and Complication Risk From Radical Cystectomy: Identifying a Body Mass Index Threshold. October 25, 2022

Repeat transurethral resection (reTURBT) of muscle invasive bladder cancer prior to radical cystectomy is prognostic but not therapeutic. October 25, 2022

Comparative cost-effectiveness of neoadjuvant chemotherapy regimens for muscle-invasive bladder cancer: Results according to VESPER data. October 24, 2022

Page 4 of 446

email news signup